All In Biotech

Drug Trial Radar · NCT01139515

Eletriptan Pharmacokinetics In Korean Males

An Open Label, Single And Repeat Dose Randomized Crossover Study To Estimate The Pharmacokinetics And Safety Of Eletriptan Hydrobromide Tablets In Healthy Korean Male Subjects

Last checked: Nov 19, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

16

Actual

Start

Jul 2010

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Sponsor type
Industry
First posted
Jun 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The hypothesis of this study is that Korean subjects have similar Pharmacokinetics (PK) characteristics to those seen in other populations.

Conditions

  • Healthy

Interventions

  • Eletriptan commercial tabletDrug

    20 mg tablet, single dose

  • Eletriptan commercial tabletDrug

    40 mg tablet, single dose of 1 X 40 mg

  • Eletriptan commercial tabletDrug

    40 mg tablet, single dose of 2 X 40 mg

  • Eletriptan commercial tabletDrug

    40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]Time frame: Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose(D)
  2. AUC From Time Zero to Last Quantifiable Concentration (AUClast)Time frame: Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)
  3. Maximum Observed Plasma Concentration (Cmax)Time frame: Pre-dosing, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hrs post dose (A,B,C) and additional 2.5,2.75,3.5,5,14,18 and 26 hrs post dose (D)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.